Research
Hormonal
Once-weekly semaglutide improves cardiometabolic markers including HbA1c, fasting plasma glucose, blood pressure, and lipid profiles in overweight/obese patients, independent of or alongside weight loss.
Beyond weight loss, semaglutide helps improve blood sugar control (HbA1c), blood pressure, and lipid profiles in overweight/obese individuals, offering broader cardiovascular protection.
StrongSupportsHIGH confidence
Semaglutide also reduced BMI and WC, and benefited glycaemic, blood pressure and triglyceride regulation.
Why this rating
Meta-analysis of 9 RCTs.
Source
Effects of once-weekly semaglutide in obese/overweight patients: A systematic review and meta-analysis
Mengjun Wang et al. · Research Square · 2022
Meta-analysis · 9 studies
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →